Notably, TRUDI represents the first and only ongoing trial combining an anti-HER2 ADC with immunotherapy in HER2-expressing IBC, highlighting a novel therapeutic approach [79]. The gene discussed is ERBB2; the disease is inflammatory breast carcinoma.